NasdaqGS - Nasdaq Real Time Price USD
DexCom, Inc. (DXCM)
82.29 +2.36 (+2.95%)
At close: October 30 at 4:00:01 PM EDT
83.50 +1.21 (+1.47%)
After hours: October 30 at 4:35:29 PM EDT
Trade DexCom on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for DXCM
What's happening with DXCM?
Powered by Yahoo ScoutDexCom delivered a strong Q3 2026, with revenue up 11.2% to $1.34 billion and adjusted EPS (earnings per share) of $0.73, above expectations. Management raised full-year revenue guidance, while new products, clinical evidence, and broader coverage could support expansion among non-insulin Type 2 diabetes patients.
Powered by Yahoo Scout
- Previous Close
79.93 - Open
81.52 - Bid 77.21 x 200
- Ask 89.80 x 200
- Day's Range
79.79 - 85.25 - 52 Week Range
54.11 - 92.59 - Volume
8,637,191 - Avg. Volume
4,506,070 - Market Cap (intraday)
30.69B - Beta (5Y Monthly) 1.48
- PE Ratio (TTM)
32.40 - EPS (TTM)
2.54 - Earnings Date Oct 29, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
97.96 - Morningstar Rating Rating available with Stock Picks access
Recent News
View More
Performance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
DXCM
23.99%
S&P 500 (^GSPC)
10.73%
1-Year Return
DXCM
20.66%
S&P 500 (^GSPC)
11.11%
3-Year Return
DXCM
3.09%
S&P 500 (^GSPC)
81.91%
5-Year Return
DXCM
47.18%
S&P 500 (^GSPC)
64.59%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 10/30/2026
Market Cap
30.70B
Enterprise Value
30.28B
Trailing P/E
32.41
Forward P/E
26.51
PEG Ratio (current)
2.72
Price/Sales (ttm)
6.31
Price/Book (mrq)
12.11
Enterprise Value/Revenue
5.93
Enterprise Value/EBITDA
18.78
Financial Highlights
Profitability and Income Statement
Profit Margin
19.42%
Return on Assets (ttm)
11.13%
Return on Equity (ttm)
37.67%
Revenue (ttm)
5.1B
Net Income Avi to Common (ttm)
991M
Diluted EPS (ttm)
2.54
Balance Sheet and Cash Flow
Total Cash (mrq)
1.82B
Total Debt/Equity (mrq)
54.94%
Levered Free Cash Flow (ttm)
811.9M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreDexCom Earnings: Smooth Sailing Signals Full Recovery From 2025
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Raising target price to $31.00
TRUPANION INC has an Investment Rating of HOLD; a target price of $31.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
Argus Innovation Theme Stocks
The United States economy is full of innovation. It has to be. Manufacturing industries that dominated the economy decades ago - textiles, televisions, even automobiles to a large degree - have moved overseas, where labor and materials costs are lower. Yet the U.S. economy, even during the pandemic and the recent period of high inflation, has expanded to record levels. If U.S. corporations weren't innovating, creating new products (such as AI and vaccines) and services (such as Zoom calls and Netflix), as well as moving into new markets (clean energy, rare drugs), the domestic economy would not be growing, and capital would not be flooding into the country. Consider that U.S. GDP was approximately $1 trillion in 1930 but was almost $31.5 trillion at the end of 2025. That's growth of 30-times. Meanwhile, the U.S. population has grown less than 3-times during that time span, to 340 million from 120 million. The delta between GDP growth and population growth has been driven, in large part, by innovation.
Raising target price to $30.00
TRUPANION INC has an Investment Rating of HOLD; a target price of $30.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.